New Leaf Venture Overview

  • Investor Type
  • Venture Capital

  • Status
  • Active

  • Professionals
  • 4

Professionals

  • Investments
  • 252

  • Portfolio
  • 22

  • Exits
  • 168

Exits

New Leaf Venture General Information

Description

Founded in 2005, New Leaf Venture Partners is a venture capital investment firm based in New York, New York. The firm is focused on healthcare technology-focused and seeks to invest in the biopharmaceutical, information convergence, medical device, biological research, life science tool, and infrastructure sectors.

Contact Information

Year Founded
2005
Investor Status
Actively Seeking New Investments
Trade Association
National Venture Capital Association (NVCA)
Primary Investor Type
Venture Capital
Other Investor Types
Growth/Expansion
Primary Office
  • 156 Fifth Avenue
  • Suite 820
  • New York, NY 10010
  • United States
+1 (646) 000-0000

New Leaf Venture Investments (252)

Company Name Deal Date Deal Type Deal Size Industry Company Stage Lead Partner
Harpoon Therapeutics 23-Oct-2023 PIPE 00000 Drug Discovery Generating Revenue/Not Profitable 000000 0000
Star Therapeutics 05-Sep-2023 00000 00000 0000 Biotechnology Clinical Trials - Phase 1
Harpoon Therapeutics 27-Mar-2023 0000 0000 Drug Discovery Generating Revenue/Not Profitable 000000 0000
Kalderos 09-Sep-2022 00000 00000 000.00 Business/Productivity Software Generating Revenue
Arine 17-Aug-2022 00000 00000 0000 Outcome Management (Healthcare) Generating Revenue
Cleerly 25-Jul-2022 00000 00000 00000 Decision/Risk Analysis Generating Revenue 00000 00000
Cleerly 11-Mar-2022 00000 00000 000.00 Decision/Risk Analysis Generating Revenue
Electra Therapeutics 16-Feb-2022 00000 00000 0000 Drug Discovery Clinical Trials - Phase 1 00000 00000
Star Therapeutics 16-Feb-2022 Early Stage VC 00000 Biotechnology Clinical Trials - Phase 1 0000000 0000
Neurana Pharmaceuticals 16-Nov-2021 Later Stage VC 0000 Drug Discovery Out of Business 000000 0000
You’re viewing 10 of 252 investments. Get the full list »

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

New Leaf Venture Exits (168)

Company Name Exit Date Exit Type Exit Size
DICE Therapeutics 09-Aug-2023 Merger/Acquisition 00.00
Glympse Bio 09-Aug-2023 000000000000000000
Braeburn 01-Aug-2023 000000000 00000000
Bluesight 17-Jul-2023 0000000000
Escape Bio 01-Sep-2022 0000000000: 000000
Akili Interactive 19-Aug-2022 0000000 000000
Sierra Oncology 01-Jul-2022 000000000000000000 00.00
ReViral 06-Apr-2022 000000000000000000 00000
Karus Therapeutics 01-Oct-2021 Secondary Transaction - Private
DICE Therapeutics 15-Sep-2021 IPO 00000
You’re viewing 10 of 168 exits. Get the full list »

New Leaf Venture Fund Performance

Fund Name Vintage Size Dry Powder DPI RVPI TVPI IRR

This information is available in the PitchBook Platform. To explore New Leaf Venture‘s full profile, request access.

Request a free trial

New Leaf Venture Investments by Industry, Year, and Region

Investments by Industry

Investments by Year

Investments by Region

PitchBook’s data visualizations quickly surface an investor’s historical investments—showing a breakdown of activity by industry, year and region.

Request a free trial

New Leaf Venture Team (46)

Name Title Deals Funds Boards Office
Craig Slutzkin Chief Financial Officer & Chief Operating Officer New York, NY
Ronald Hunt Co-Founder & Managing Director 00 0 0 New York, NY
Vijay Lathi Co-Founder & Managing Director 00 0 0 New York, NY
Sam Brasch Managing Director 00 0 New York, NY
Martin Mackay Ph.D Senior Advisor 0 0 New York, NY
You’re viewing 5 of 46 team members. Get the full list »

New Leaf Venture Co-Investors (164)

Name With Exits Lead Partner Series Industry
OrbiMed 6 0 0 Series chart Industry bar
Novo Holdings 0 0 0 Series chart Industry bar
RA Capital Management 0 0 0 Series chart Industry bar
Cormorant Asset Management 0 0 Series chart Industry bar
Logos Capital 0 0 0 Series chart Industry bar
You’re viewing 5 of 164 co-investors. Get the full list »